Huntington's disease

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Retrieved on: 
월요일, 8월 28, 2023
Huntington's disease, Pit additive, KINECT, Lancet Neurology, Week, Disease, McGovern Medical School, Neurocrine Biosciences, Clinical Global Impression, Movement disorder, The Lancet, MDS, Capsule, Movement, TMC, SAN, Chorea, Parkinson's disease, FANA, Neurology, Poster, FAAN, FDA, Safety, Pharmaceutical industry, HD

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD), including exploratory results from the Phase 3 KINECT®-HD study, which showed consistently greater improvements in HD chorea with INGREZZA versus placebo from Week 2 to Week 12. These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.

Key Points: 
  • These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.
  • "The exploratory analysis from our KINECT-HD study further exemplifies the value of INGREZZA as a now approved medication for HD chorea with improvements seen with treatment as early as two weeks," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • "This exploratory analysis has increased our insight regarding the early and sustained improvements in chorea severity."
  • Additional HD chorea presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders include:

First Tunisian study examining age of onset for biallelic mutations in Huntington's disease

Retrieved on: 
일요일, 8월 27, 2023
HD, Huntington's disease, Zygosity, University, HTT, Disease, Allele, Huntingtin, Mutation, Doctor of Philosophy, CAG, Movement, Patient, University of Lisbon, Parkinson's disease, International Congress on Tuberculosis, Autosome, Pharmaceutical industry, Vaccine

This Tunisian cohort study reported that the age of disease onset for patients with a homozygous mutation in the Huntingtin gene (HTT) did not differ significantly from that of heterozygous patients.

Key Points: 
  • This Tunisian cohort study reported that the age of disease onset for patients with a homozygous mutation in the Huntingtin gene (HTT) did not differ significantly from that of heterozygous patients.
  • The age of disease onset between the homozygous and heterozygous patients did not differ significantly.
  • Patients with smaller all were associated with a later age of onset, 62 years for homozygous and 74 years for heterozygous.
  • The number of CAG repeats and age of disease onset was shown to be inversely correlated for homozygous patients.

Family Building & Genetics: The Prelude Network® to Sponsor the 3rd Annual HelpCureHD Gala and Inaugural Educational Forum

Retrieved on: 
수요일, 8월 23, 2023
HD, Reproductive medicine, PGT, Education, Neurodegenerative disease, Quality of life, Aspire, Huntington's disease, Research, Infertility, IVF, Physician, Risk, Child, Fertility, Inception, Miscarriage, Genetic testing, Gala, DSM-IV codes, Disease, Birth control, Pharmaceutical industry, Prelude, Neurology

HOUSTON, Aug. 23, 2023 /PRNewswire/ -- The Prelude Network® (Prelude), the largest and fastest-growing network of fertility centers in North America, announces today its sponsorship of the 2023 HelpCureHD's Gala & Forum, scheduled to take place on September 7, 2023, in Houston. This event is designed to raise awareness around and funds for Huntington's Disease (HD), an inheritable and progressive neurodegenerative disease for which no known cure exists.

Key Points: 
  • This event is designed to raise awareness around and funds for Huntington's Disease (HD), an inheritable and progressive neurodegenerative disease for which no known cure exists.
  • Dr. Reem Sabouni with Aspire Houston Fertility Institute (Aspire HFI), part of Prelude, will be a panelist at the forum.
  • HelpCureHD is a nonprofit that aims to help improve the quality of life for those affected by HD.
  • To learn more about the event and how to reserve your tickets, please visit www.helpcurehd.org/2023-helpcurehd-gala .

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

Retrieved on: 
금요일, 8월 18, 2023
Huntington's disease, Maintenance, VMAT2, Chorea, Depression, Pharmacy, Somnolence, Disease, Huntington's Disease Society of America, Neurocrine Biosciences, Quality of life, Medicine, NMS, Hives, Behavior, Rash, HSG, Insomnia, Capsule, LSM, TMC, Patient, McGovern Medical School, Neuroleptic malignant syndrome, SAN, FANA, Suicidal ideation, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FAAN, Food, Caregiver, Safety, Pharmaceutical industry, Birth control, HD, Neurology

"We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."

Key Points: 
  • "We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."
  • In clinical studies in Huntington's disease, treatment-emergent adverse events included somnolence and sedation, urticaria, rash and insomnia.
  • "Data also demonstrated INGREZZA was generally well tolerated and showed clinically meaningful improvement in adults with chorea associated with HD."
  • "The approval of INGREZZA for HD chorea means that people living with HD have a new treatment option to help manage their chorea symptoms, which is a welcomed milestone in efforts to improve care for families affected by HD."

AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Retrieved on: 
목요일, 8월 3, 2023
Muscular dystrophy, Heart, Huntington's disease, Arm, Hearing, Bayer, Quality of life, Weakness, B cell, Multiple system atrophy, Glycogen storage disease type II, Leg, Department of Neurology, Xuanwu hospital, Doctor of Philosophy, RESEARCH, FKRP, Wasting, Parkinson's disease, MD, Patient, European, Knowledge, Entrepreneurship, Research, FDA, VCU School of Medicine, Safety, PARK, LGMD, Disease, Pharmaceutical industry

Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9.

Key Points: 
  • Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9.
  • "Hearing that the first patient has been dosed in this study evaluating AB-1003 is an exciting moment for the limb-girdle muscular dystrophy community and individuals living with this debilitating disease," said Kelly Brazzo, Co-Founder & CEO, CureLGMD2i.
  • "Given the current lack of disease modifying treatments for LGMD, many in the community know of the potential of gene therapy.
  • The initiation of this trial offers hope that patients with this condition may, in the future, have a significantly improved quality of life."

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

Retrieved on: 
목요일, 8월 3, 2023
GLP, HD, GBA1, Gene, Ataxia, HTT, Conference call, Disease, Telephone, Neurocrine Biosciences, Neurocrine, TRACER, G&A, Huntington's disease, Research, Brain, CNS, Small RNA, SOD1, Novartis, Prion, FXN, MSH3, Annual general meeting, Cell, Toxicology, Mouse, Sirna Therapeutics, Growth, FDA, Therapy, ALS, IND, Neurology, Conference, Society, Sangamo Therapeutics, VY, D, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Voyager

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.
  • Collaboration Revenues: Voyager had collaboration revenue of $4.9 million for the second quarter of 2023, compared to $0.7 million for the same period in 2022.
  • The increase was primarily due to revenue recognized during the second quarter of 2023 on the 2023 and 2019 strategic collaborations with Neurocrine Biosciences.
  • ET to discuss the second quarter 2023 financial and operating results.

Huntington Bank Names Marcy Hingst General Counsel

Retrieved on: 
수요일, 8월 2, 2023
Tufts University, Wealth, Ohio State University, Huntington's disease, General counsel, Bank Secrecy Act, Huntington Bancshares, Bank of America, Hingst, O'Melveny & Myers, Consumer, Small business, Bank, Investment, Management

COLUMBUS, Ohio, Aug. 2, 2023 /PRNewswire/ -- The Huntington National Bank ("Huntington") announced today the appointment of Marcy Hingst as General Counsel. Hingst will join the bank's Executive Leadership Team and oversee all legal activities for the company.

Key Points: 
  • COLUMBUS, Ohio, Aug. 2, 2023 /PRNewswire/ -- The Huntington National Bank ("Huntington") announced today the appointment of Marcy Hingst as General Counsel.
  • Hingst joins the bank from Bank of America, where she most recently served as the Global Financial Crimes Executive, Bank Secrecy Act Officer and Chief Risk Officer for the Global Wealth and Investment Management lines of business.
  • "We look forward to her becoming our General Counsel, joining our Executive Leadership Team and leading our legal group."
  • Prior to her current role, Hingst served as Bank of America's Chief Risk Officer for the Consumer and Small Business Banking segments and, before that, as Deputy General Counsel for those lines of business.

UT Health Science Center San Antonio recognized as Parkinson's Foundation Comprehensive Care Center

Retrieved on: 
화요일, 8월 1, 2023
Workforce, Huntington's disease, Deep brain stimulation, Hallucination, University, Center of excellence, Tic, Parkinson's Foundation, University of Texas System, University of Texas Health Science Center at San Antonio, Senior counsel, DSM-IV codes, Therapy, Health, Parkinson's disease dementia, Quality of life, UT Health San Antonio Cancer Center, Research, Brain, Neurology, Department of Neurology, Xuanwu hospital, Dystonia, Bone, Movement, Teaching hospital, Essential tremor, Pain, Social, DBS, Electrode, Parkinson's disease, Neurosurgery, MD, Patient, SAN, Person-centered therapy, Rush Alzheimer's Disease Center, Long School, Long School of Medicine, Movement disorder, Bleeding, Memory, Skin, Disease, Pharmaceutical industry, Nursing, Veterinary medicine, Dentistry, Central Texas

SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.

Key Points: 
  • Advanced multidisciplinary care for Parkinson's disease is available at The University of Texas Health Science Center at San Antonio, which this summer was named a Parkinson's Foundation Comprehensive Care Center.
  • SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.
  • The UT Health San Antonio Movement Disorders Center is also recognized as a Huntington's Disease Center of Excellence and provides comprehensive care for patients with Huntington's disease.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.

HUNTINGTON BANCSHARES INCORPORATED INCREASES ITS PRIME RATE TO 8.5 PERCENT

Retrieved on: 
목요일, 7월 27, 2023
Huntington's disease, HBAN, Rare-earth element, Gasoline, Air cargo

COLUMBUS, Ohio, July 27, 2023 /PRNewswire/ -- Huntington Bancshares Incorporated (Nasdaq: HBAN) announced that its prime rate is increasing from 8.25 percent to 8.5 percent, effective July 27, 2023.

Key Points: 

COLUMBUS, Ohio, July 27, 2023 /PRNewswire/ -- Huntington Bancshares Incorporated (Nasdaq: HBAN) announced that its prime rate is increasing from 8.25 percent to 8.5 percent, effective July 27, 2023.
Huntington's rate last changed on May 4, 2023, increasing from 8 percent to 8.25 percent.

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Retrieved on: 
수요일, 7월 12, 2023
Vaccine, GMP, Huntington's disease, DNA, Business development, Weill Cornell Medicine, Tau, N8 Research Partnership, Therapy, Speech, Neurodegenerative disease, Dementia, Research, IRBM, Doctor of Philosophy, Tauopathy, Richard Rainwater, Organization, Frontotemporal dementia, Parkinson's disease, HIV disease progression rates, RCF, Drug discovery, Pain scale, AD, Rain, Alzheimer's disease, PSP, Pharmaceutical industry

The collaboration brings together IRBM’s capabilities in drug discovery and development, RCF’s medical research resources via the Tau Consortium, and the expertise of Weill Cornell Medicine neuroscientist Dr. Li Gan to pursue innovative therapies for neurodegenerative disorders.

Key Points: 
  • The collaboration brings together IRBM’s capabilities in drug discovery and development, RCF’s medical research resources via the Tau Consortium, and the expertise of Weill Cornell Medicine neuroscientist Dr. Li Gan to pursue innovative therapies for neurodegenerative disorders.
  • We are therefore privileged to start our work on Alzheimer’s with renowned specialists in the area: Rainwater Charitable Foundation and Weill Cornell Medicine.
  • Weill Cornell Medicine Enterprise Innovation negotiated and helped facilitate the collaboration between Dr. Gan and the RCF with the aim to support efforts to discover new therapies for debilitating neuro-degenerative diseases.
  • For more information, please visit www.irbm.com
    The Rainwater Charitable Foundation was founded by Texas investor and philanthropist Richard Rainwater in 1991 to support childhood-focused initiatives.